Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422124 | 0.80 | GID4 (0.54) | SMN1; SMN2MAOBGID4KMT2AMEN1 | |
| SCHEMBL12200972 | 0.77 | GAA (0.65) | RAB9ANPC1SMN1; SMN2POLBTP53 | |
| SCHEMBL3427764 | 0.77 | SMN1; SMN2 (0.69) | SMN1; SMN2MAOBGID4KMT2AMEN1 | |
| SCHEMBL7686538 | 0.75 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL3424863 | 0.75 | SMARCA2 (0.69) | SMN1; SMN2MAOBGID4TP53KMT2A | |
| SCHEMBL3428344 | 0.74 | MAPK1 (0.70) | SMN1; SMN2POLBTDP1MAOBGID4 | |
| SCHEMBL19583412 | 0.74 | GAA (0.69) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL2245506 | 0.74 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL711507 | 0.73 | PKM (0.71) | RAB9ANPC1SMN1; SMN2POLBTP53 | |
| SCHEMBL31734838 | 0.73 | PKM (0.71) | RAB9ANPC1SMN1; SMN2POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673356-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | Newron Pharmaceuticals S.p.A. (IT) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040138-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-05-06 | — | — | WO | claimed |
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | disclosed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| EP-1673356-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | Newron Pharmaceuticals S.p.A. (IT) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040138-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-05-06 | — | — | WO | disclosed |
| EP-1524267-A1 | Substituted benzylaminoalkylene heterocycles | Newron Pharmaceuticals S.p.A. (IT) | 2005-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | HTR7, MAOB, CYP2A7 | RAB9A 1487/4885NPC1 1404/4885SMN1; SMN2 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.